Entrada Therapeutics (TRDA) Retained Earnings (2022 - 2025)
Historic Retained Earnings for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$233.9 million.
- Entrada Therapeutics' Retained Earnings fell 7925.67% to -$233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$233.9 million, marking a year-over-year decrease of 7925.67%. This contributed to the annual value of -$129.3 million for FY2024, which is 3365.95% up from last year.
- Latest data reveals that Entrada Therapeutics reported Retained Earnings of -$233.9 million as of Q3 2025, which was down 7925.67% from -$189.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Retained Earnings ranged from a high of -$115.3 million in Q1 2022 and a low of -$233.9 million during Q3 2025
- Its 4-year average for Retained Earnings is -$168.0 million, with a median of -$171.5 million in 2024.
- Its Retained Earnings has fluctuated over the past 5 years, first soared by 4728.7% in 2024, then crashed by 7925.67% in 2025.
- Over the past 4 years, Entrada Therapeutics' Retained Earnings (Quarter) stood at -$188.3 million in 2022, then decreased by 3.55% to -$195.0 million in 2023, then skyrocketed by 33.66% to -$129.3 million in 2024, then plummeted by 80.86% to -$233.9 million in 2025.
- Its last three reported values are -$233.9 million in Q3 2025, -$189.8 million for Q2 2025, and -$146.7 million during Q1 2025.